FBN1 and Marfan syndrome: Based on these numbers, we estimate that the overall prevalence of MFS in Iceland could be as high as 1 in 6,600 (40 with a pathogenic/likely pathogenic variant in FBN1 + 10 not genotyped MFS patients/without an identified FBN1 variant, among 329,100 Icelanders).